Thousand Oaks Biopharmaceuticals

What Thousand Oaks Biopharmaceuticals does

Thousand Oaks Biopharmaceuticals (澳斯康生物), legally Aosikang Biological (Nantong) Co., Ltd., is a privately held Chinese biopharmaceutical CRDMO founded in 2011 and headquartered in Haimen, Jiangsu Province. The company operates an integrated Contract Research, Development and Manufacturing Organization platform with three business segments: (1) early research services through its Ginspire subsidiary offering eight technology platforms spanning AI-based antibody modeling, antibody discovery, novel linker-payload chemistry, pharmacology/toxicology, druggability assessment, early sample preparation, structural characterization, and complex molecule design; (2) cell culture media through its Jianshun Bio subsidiary, with over 100 commercialized serum-free, chemically defined formulations across CHO, HEK-293, insect, vaccine, T/NK and stem cell lines, and three thousand-ton-scale production bases in Lanzhou, Nantong, and Busan; and (3) biologics CDMO through Shanghai Aosikang Biopharmaceutical, providing end-to-end CMC services from cell line development through clinical and commercial manufacturing for monoclonal antibodies, bispecific antibodies, ADCs, and recombinant proteins.

The company's proprietary technology foundation includes the MeCHOta CHO-K1 cell line platform (licensed from ECACC with full traceability), the pTOB proprietary expression vector system, a linker-payload library covering MC-VC-PAB-MMAE, MC-GGFG-DXd, Exatecan derivatives, and proprietary TOP1i-based payloads, and an AI prediction platform built on locally deployed AlphaFold3 and IgFold for developability assessment. Manufacturing infrastructure spans over 40,000 m² across China, complemented by Korea-based CCM3 production and a US headquarters in Pleasanton, California. Multi-jurisdictional regulatory compliance includes five successful PAI inspections, EU QP audit pass (October 2025), NMPA/FDA/EMA GMP certification, and ISO 13485/9001/14001/45001 plus FSSC 22000 and HALAL certifications.

The business model combines project-based CDMO contracts (charged by development stage or production batch with multi-year terms), commercial sale of cell culture media products in various pack sizes from 500mL to bulk ton-scale, and professional services for early research. Customer concentration skews toward Chinese innovative biotech and vaccine manufacturers, with notable relationships including CanSino Biologics (exclusive media provider for adenoviral COVID-19 vaccine), Hengrui Pharmaceuticals, Boan Biology, and Jiahe Bio. The company employs 501–1000 staff and has raised over 2.6 billion RMB across four funding rounds from 2019–2021, submitted an IPO application in June 2022, and was recognized as a Jiangsu Unicorn Enterprise.

Name

Thousand Oaks Biopharmaceuticals

Legal name

澳斯康生物（南通）股份有限公司

Website

https://tobiopharm.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Thousand Oaks Biopharmaceuticals is a Chinese biopharmaceutical CRDMO offering integrated cell culture media, biologics CDMO, and early-stage R&D services to global biopharma companies developing monoclonal antibodies, bispecific antibodies, ADCs, and vaccines.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Biopharmaceutical CDMO services
• Cell culture media
• Antibody drug conjugates
• Biologics contract manufacturing
• Early research services

Headquarters

HQ city

Haimen

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Biopharmaceutical CDMO Services: Full-service contract development and manufacturing for biologics including recombinant proteins, monoclonal antibodies, bispecific antibodies, ADCs, and vaccines. Services span from candidate molecule through clinical and commercial production. Revenue is generated through project-based contracts, typically charged per development stage or production batch.
2. Cell Culture Media Products and Custom Development: Sale of commercialized cell culture media products and custom formulation development services. Products sold in various pack sizes (500mL to 100L or bulk ton-scale). Includes serum-free, chemically defined media for multiple cell types used in recombinant protein, vaccine, and cell therapy production.
3. Early Research Services (Ginspire): Early-stage drug discovery and development services including molecular design, antibody discovery, ADC linker-payload development, developability assessment, pharmacological evaluation, and early sample preparation. Services delivered through the Ginspire subsidiary.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Thousand Oaks Biopharmaceuticals (Aosikang Biological / 澳斯康生物) operates an integrated CRDMO platform combining cell culture media (Jianshun Bio 健顺生物) with biologics contract development and manufacturing services (Aosikang Biopharmaceutical) and early-stage research services (Ginspire 健士拜生物). It sells over 100 commercialized serum-free and chemically defined cell culture media formulations, develops proprietary CHO-K1 and HEK-293 cell lines, and provides end-to-end CMC services from candidate molecule through clinical and commercial manufacturing for monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and recombinant proteins.

Product overview

Thousand Oaks Biopharmaceuticals (澳斯康生物) operates as an integrated CRDMO (Contract Research, Development and Manufacturing Organization) with three core business segments: (1) Early research services through Ginspire (健士拜生物) providing end-to-end solutions from molecular design to development with 8 technology platforms including AI prediction, antibody discovery, ADC linker-payload, pharmacology/toxicology, druggability assessment, early sample preparation, structural characterization, and innovative complex molecule design; (2) Cell culture media business through Jianshun Bio (健顺生物) offering over 100 commercialized serum-free cell culture media products for CHO, HEK-293, insect cells, vaccine production cells, T/NK cells, and stem cells with thousand-ton annual production capacity across China and Korea; (3) Biologics CDMO services through Aus康生物制药 providing one-stop CMC solutions from candidate molecule to clinical and commercial manufacturing for monoclonal antibodies, bispecific antibodies, ADCs, fusion proteins, and recombinant proteins. The company's proprietary MeCHOta CHO-K1 cell line platform enables high-expression recombinant protein production. Manufacturing infrastructure includes macro-molecule drug commercialization base in Nantong, ADC R&D and GMP production center in Shanghai, and three cell culture media production bases (Lanzhou CCM1, Nantong CCM2, Busan CCM3) plus US headquarters in California.

Differentiator

Problem solved

Functional benefit

Brands

• Jianshun Bio (健顺生物): Cell culture media business unit providing serum-free and chemically defined media for biopharmaceutical production
• Ginspire (健士拜生物)
• MeCHOta
• TransCHO Kit Pro
• Trans293 Kit

Quantifiable outcome

• Up to 17x increase in vaccine production efficiency through custom media and perfusion process development
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• KCell Biosciences and Busan Metropolitan GovernmentcoreStrategic or Co-development Partner · 1 September 2025Strategic cooperation memorandum signed September 2025 between Busan Metropolitan Government, Auskang Group, and KCell Biosciences to promote biotech innovation and empower emerging industries in Busan.
• Kexing Pharmaceutical (科兴制药)coreStrategic or Co-development Partner · 1 September 2025Strategic partnership established September 2025 with Kexing Pharmaceutical for biosimilar R&D and industrialization of KXBS001 project.
• Multiple Strategic Partners (Ginspire Launch)coreStrategic or Co-development Partner · 1 February 2025Ginspire platform launch event February 2025 was attended by 60+ industry customers and Zhangjiang Group representatives. Multiple strategic collaboration discussions initiated at the event.
• China Agricultural University (中农威特)minorStrategic or Co-development Partner · 1 May 2021Strategic partnership established May 2021 with China Agricultural University's biotech subsidiary for veterinary vaccine development and production.
• KCell Biosciences (Korea)coreStrategic or Co-development Partner · 1 January 2021Joint venture established in January 2021 with Korean partner WSG Group for serum-free cell culture media business in Korea. Auskang holds ownership stake in the venture, expanding Asia-Pacific supply chain and market presence in the Korean biopharma market.
• Boan Biology (博安生物)coreStrategic or Co-development Partner · 1 September 2020Strategic partnership established September 2020 with，绿叶制药 subsidiary Boan Biology for multiple clinical project media development and supply services.
• Hengyuan (恒瑞医药)coreStrategic or Co-development Partner · 1 May 2020Strategic cooperation agreement signed May 2020 with Hengrui Medicine for cell culture media development and supply services. Hengrui is a leading Chinese innovative drug developer.
• BTI (Biologics Processing Institute, A*STAR Singapore)coreStrategic or Co-development Partner · 1 October 2018Strategic partnership established October 2018 with Singapore's Biologics Processing Institute (BTI) under A*STAR. Jointly established CMC biomanufacturing process development laboratory, combining BTI's research capabilities with Auskang's industrialization expertise.
• Jiahe Bio (嘉和生物)coreStrategic or Co-development Partner · 1 July 2017Long-term strategic partnership established July 2017 with Jiahe Bio (a leading Chinese monoclonal antibody company) for serum-free cell culture media supply.
• Valneva (France)coreStrategic or Co-development Partner · 1 March 2015Exclusive cooperation agreement signed March 2015 with French biotech company Valneva for the EB66 cell line project in China. Valneva is a leading French biotech specializing in vaccines.

Scale indicators9 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• WuXi Biologics: China's largest biologics CDMO offering end-to-end development and manufacturing for mAbs, bispecifics, ADCs, and recombinant proteins. Most directly comparable Chinese peer with overlapping capabilities across cell line, upstream/downstream, and fill-finish, though at materially larger scale.
• GenScript ProBio: Chinese CDMO offering plasmid, viral vector, and protein/antibody services including cell line development. Comparable Chinese peer in biologics CDMO space with overlapping cell line and upstream process capabilities, though focused more on gene therapy adjacent services.

Broad incumbents

• Lonza Group: Swiss global CDMO leader with extensive biologics manufacturing capacity including cell culture media and ADC services. Comparable end-to-end CRDMO model but at much greater global scale and broader modality coverage including cell and gene therapies.
• WuXi STA (WuXi AppTec): Chinese CRDMO offering both small molecule and biologics services including ADC and cell culture media capabilities. Comparable vertical integration model and Chinese customer base, but with broader service portfolio and stronger global brand recognition.
• Catalent (Novo Holdings): US-headquartered global CDMO with biologics, ADC, and fill-finish capabilities. Comparable end-to-end biologics CDMO services for global biopharma, though much larger scale and primarily serves North American/European customers.
• AGC Biologics: Global CDMO with mammalian and microbial biologics manufacturing including ADC capabilities. Comparable end-to-end biologics CDMO model with strong regulatory track record, though geographically concentrated in Europe/US/Japan rather than China.

Regional players

• Samsung Biologics: Korean biologics CDMO with very large single-site bioreactor capacity serving global clients. Highly relevant regional peer given Thousand Oaks' Korean Busan JV and shared APAC customer base, though Samsung focuses on large-molecule manufacturing rather than integrated media+CDMO.
• Bora Pharmaceuticals: Taiwanese CDMO with biologics manufacturing capabilities including cell culture and fill-finish. Comparable Asia-Pacific CDMO serving regional customers, though with different geography and limited media business.

Others

• Cytiva (Danaher): Global life sciences tools provider offering cell culture media, bioreactors, and bioprocessing equipment plus CDMO services. Direct overlap in cell culture media product portfolio and an enabler/supplier to many of Thousand Oaks' CDMO peers and customers.
• Merck MilliporeSigma: Global life sciences tools and bioprocessing leader offering cell culture media, filtration, and CDMO services. Direct competitor in cell culture media products and a key upstream supplier/enabler for bioprocessing workflows that Thousand Oaks' customers also use.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aosikang-biologics

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds6 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thousand Oaks Biopharmaceuticals